Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint

International Journal of Clinical Practice

Volumn 52, Issue 7, 1998, Pages 467-471

  Spannheimer, A ^a   Goertz, A ^b   Dreckmann Behrendt, B ^b  

^a Kendle   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; TORASEMIDE;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0031763919     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Konstam MA, Dracup K, Brooks NH et al. Heart failure: management of patients with left ventricular systolic dysfunction. Clinical Practice Guideline No. II. AHCPR Publication No. 94-0603. Rockville, MD, 1994.
2. English MA, Mastrean MB. Congestive heart failure: public and private burden. Crit Care Nurs Quart 1995; 18: 1-6.
3. Andrews R, Cowley AJ. Clinical and economic factors in the treatment of congestive heart failure. PharmacoEconomics 1995; 7: 119-127.
4. Schwartz S, Brater DC, Pound D et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torasemide in patients with cirrhosis. Clin Pharmacol Ther 1993; 54: 90-97.
5. Brenner S, Hariman RJ, Kostis JB et al. Comparison of torasemide and furosemide in moderate to severe congestive heart failure. In: Puschet JB, Ed. Diuretics V, chemistry, pharmacology and clinical applications. Amsterdam: Elsevier 1993: 49-50.
6. Stauch M, Stiehl L. Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure: a multicenter study. Prog Pharmacol Clin Pharmacol 1990; 8: 121-126.
7. Duesing R, Piesche L. Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol 1990; 8: 105-120.
8. Broekhuysen J, Dreger F, Douchamps J et al. Torasemide. a new potent diuretic. Eur J Clin Pharmacol 1986; 31(suppl): 29-34.
9. Vargo DL, Kramer WG, Black PK et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torasemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57(6): 601-609.
10. Bundesverband der Pharmazeutischen Industrie e.V., Frankfurt: Rote Liste 1996, ECV, Editio Cantor, Aulendorf.
11. Broglie G, Pranschke-Schade S, Schade H-J, Gerhardt G. Gebühren-Handbuch. Wiesbaden: Medical Tribune Verlagsgesellschaft mbH, 1996.
12. Einheitlicher Bewertungsmaßstab (EBM); Cologne: Deutscher Ärzte Verlag, 1994.
13. Statistisches Jahrbuch. Stuttgart: Metzler-Poeschel, 1996.
14. Statistisches Bundesamt, Wiesbaden, personal communication: Durchschnittsgehälter, 1996.
15. European health care reform: analysis of current strategies. WHO Regional Pulications, European Series No 72.
16. AOK. Der Gelbe Dienst. Pflegesätze der Krankenhäuser in 1995.
17. Statistisches Bundesamt Wiesbaden: Diagnosedaten der Krankenhauspatienten 1994, Gesundheitswesen Fachserie 12, Reihe 6.2; Metzler-Poeschel, Stuttgart 1996.
18. SOLVD Investigators. Effect of enalapril in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
19. Fassbinder W, Achhammer I. Improvement of prognosis of coogestive heart failure with the new loop diaretic torasemide and the impact on pharmacoeconomic aspects. (In preparation)